Porcine epidemic diarrhea (PED) caused by porcine epidemic diarrhea virus (PEDV) is widespread in the world. In recent years, the increased virulence of the virus due to viral variations, has caused great economic losses to the pig industry in many countries. It is always worthy to find effective therapeutic methods for PED. As an important class of antivirals, nucleoside drugs which target viral polymerases have been applied in treating human viral infections for half a century. Herein, we evaluated the anti-PEDV potential of three broad-spectrum antiviral nucleoside analogs, remdesivir (RDV), its parent nucleoside (RDV-N) and β-d-N4-hydroxycytidine (NHC). Among them, RDV-N was the most active agent in Vero E6 cells with EC50 of 0.31 μmol/L, and more potent than RDV (EC50 = 0.74 μmol/L) and NHC (EC50 = 1.17 μmol/L). The activity of RDV-N was further confirmed using an indirect immuno-fluorescence assay. Moreover, RDV-N exhibited a good safety profile in cells and in mice. The high sequence similarity of the polymerase functional domains of PEDV with other five porcine coronaviruses indicated a broader antiviral spectrum for the three compounds. Generally, RDV-N is a promising broad-spectrum antiviral nucleoside, and it would be worthy to make some structural modifications to increase its oral bioavailability.
Porcine epidemic diarrhea virus (PEDV) is an enteropathogenic alpha coronavirus which can cause porcine epidemic diarrhea (PED), a highly contagious swine disease that is prevalent among pig herds. PEDV was first identified in the 1970s, and in the following decades, it did not cause a significant impact on the pig industry until the emergence of new variant strains with high virulence in the 2010s. Since then, PEDV outbreaks have frequently occurred throughout the world, especially in China and some Asian countries (Lee 2015). Vaccination has been the primary measure for the prevention of PEDV. However, due to the emerging genetic variants, the current PEDV vaccines are not guaranteed to be effective. Generally, for the suckling piglets which are most vulnerable to PEDV, the mortality rate could reach 100% (Ma et al. 2015). Considering the great threat to the pig industry, it’s meaningful to find more effective methods for the prophylaxis and treatment of PED in the long run.
Besides vaccination, some potential therapeutic methods for PED have also been reported, such as neutralizing antibodies (Gong et al. 2018; Zhang et al. 2019), anti-inflammatory factor (Li et al. 2019), peptides (Zhao et al. 2018), and small chemical molecules. Among them, small chemical molecules including natural products and synthetic compounds attract the most attention. Glycyrrhizin and glycyrrhizic acid, two active components of glycyrrhiza uralensis that is a common Chinese herb, have been characterized with various biological activities. Recently, the two compounds are found to effectively inhibit the PEDV infection in Vero cells by multisite inhibition mechanisms (Huan et al. 2017; Tong et al. 2020). The oleanane triterpenes and prenylated phenolic compounds from natural plants are also identified as PEDV proliferation inhibitors, some of them could inhibit viral replication at sub-micro molar level (Cho et al. 2019; Yang et al. 2015). In 2020, Peng et al. reported that GC376, a well-known broad-spectrum inhibitor of 3CLpro was highly effective against the PEDV 3CLpro with IC50 value of 1.11 µmol/L. The structural basis for inhibiting this enzyme was elucidated, providing important information for the structural optimization of GC376 (Ye et al. 2020).
At the end of 2019, a new human coronavirus, named SARS-CoV-2 emerged and rapidly spread around the world, infecting nearly 98 million people and causing more than 2.0 million deaths by January 21st, 2021 (Valencia 2020). During this pandemic, an antiviral drug, remdesivir (RDV), which was previously indicated for Ebola virus infection, was authorized for emergency use against the viral infection on May 1st, 2020, and officially approved soon based on the positive results of three clinical trials (Beigel et al. 2020; Goldman et al. 2020; Spinner et al. 2020). RDV is a 1′-cyano-substituted adenosine nucleotide analogue prodrug which acts as a non-obligated chain terminator by targeting the highly conserved active site of viral polymerase and shows broad-spectrum antiviral activity against an array of RNA viruses, such as HCV, MERS virus, SARS-CoV virus, and Ebola virus (Agostini et al. 2018; Cho et al. 2012; Siegel et al. 2017). Moreover, this antiviral candidate is found to be able to inhibit zoonotic deltacoronaviruses with highly divergent RNA dependent RNA polymerases (RdRps), highlighting the value of this drug in the fighting against future emerging viruses (Brown et al. 2019). β-d-N4-hydroxycytidine, NHC, reported as early as 1959 (Fox et al. 1959) is also found to be a broad-spectrum antiviral nucleoside which has recently received a great deal of attention due to its potential for the treatment of SARS-CoV-2 infection (Sheahan et al. 2020b; Yoon et al. 2018).
As is well known, nucleoside analogs are an important source for discovering antiviral agents, and till now more than twenty-five drugs of this class have been approved for treating human viral diseases (Seley-Radtke and Yates 2018; Yates and Seley-Radtke 2019). However, with respect to animal viral diseases, little is known on the therapeutic potential of such kind of antivirals. PED is a serious disease that is lethal to piglet, and it is very meaningful to find effective anti-PEDV drugs. Herein, we evaluated the anti-PEDV activities of RDV, RDV nucleoside (RDV-N), and NHC, whose molecular structures were shown in Fig. 1. We found that RDV-N was the most active antiviral relative to its prodrug, RDV, and NHC. Moreover, RDV-N exhibited a high safety profile in mice which makes it to be a promising antiviral for the treatment of PEDV infection.
Materials and Methods
Viruses, Cells and Mice
African green monkey kidney cells (Vero E6 cells) were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) at 37 °C with 5% CO2. The PEDV variant strain SDSX16 (Accession no. MH117940.1) was isolated from a sucking piglet with acute diarrhea. Male ICR mice (18–22 g) were purchased from Shanghai Super-B&K Laboratory Animal Co. Ltd. (Shanghai, China).
RDV, RDV-N, and NHC were synthesized according to the reported methods (Purohit et al. 2012; Siegel et al. 2017) and the structures were determined by nuclear magnetic resonance. The samples used for in vitro and in vivo study were in a purity of at least 98.5% by high-performance liquid chromatography analysis.
To assess the cytotoxicity of RDV/RDV-N/NHC in Vero E6 cells, cells were seeded in 96-well plates and allowed to grow for 24 h to reach 80% confluence, and then treated with the test compounds (RDV/RDV-N/NHC) diluted with serum-free DMEM containing 10 μg/mL trypsin (Sigma, St. Louis, MO, USA) at a final concentration of 500 μmol/L, 250 μmol/L, 125 μmol/L, 62.5 μmol/L and 31.25 μmol/L. DMSO was used as the blank control. The cells were then cultured at 37 °C for 72 h, and the cytotoxicity was determined by CCK-8 assay.
Anti-PEDV Activity Assay
Vero E6 cells were seeded in 96-well plates for 24 h and washed thrice with serum-free medium. PEDV (0.01 MOI) was first incubated with serial dilutions of the test compounds (RDV/RDV-N/NHC) at 37 °C for 1 h before infecting the Vero E6 cells. The final concentrations of RDV and RDV-N ranged from 125 μmol/L to 0.1 μmol/L, and the concentration of NHC ranged from 62.5 μmol/L to 0.5 μmol/L. DMSO was set as the blank control. The mixture was incubated at 37 °C until the cells of the virus control group showed complete cytopathic effect (CPE). The characteristic morphological changes of PEDV-infected cells in the antiviral groups were observed and photographed.
In another experiment, after adding the PEDV-compounds dilution to the cells, the mixture was incubated at 37 °C for 48 h and 72 h, respectively. Cells and supernatants were harvested to determine viral loads and titers using quantitative real-time RT-PCR (qRT-PCR) and 50% tissue culture infectious dose (TCID50) assay, respectively. The effective concentration that reached 50% decrease in viral replication was defined as the EC50 value.
Indirect Immuno-Fluorescence Assay (IFA)
Vero E6 cells were cultured in 24-well plates for 24 h and washed thrice with serum-free medium. PEDV (0.01 MOI) was first incubated for 1 h at 37 °C in the presence of 0.2 µmol/L RDV-N before infecting Vero cells. DMSO was used as the blank control. Viral propagation was confirmed by daily observation of the CPE. After 48 h at 37 °C, cells were fixed with 4% paraformaldehyde for 15 min at room temperature (RT) and then blocked with 1% bovine serum albumin (BSA) in PBS for 30 min at RT. The monoclonal antibody specific against PEDV spike protein was added to the cells as primary antibodies and incubated for 1 h at 37 °C. After washing three times with PBS, cells were incubated with FITC-conjugated anti-mouse IgG (Southern Biotech, Birmingham, AL, USA) in the dark for 30 min at 37 °C. After washing five times with PBS, the images were captured using a fluorescence Leica DM IL LED microscope (Leica, Wetzlar, Germany).
PEDV Genomic and Subgenomic qRT-PCR Assay
96-Well plates of Vero E6 cells were prepared, infected, and treated similarly to those described above. After 48 h or 72 h, cells were harvested and total RNA was extracted from Vero E6 cells using the TRIzol reagent (Invitrogen) according to the manufacturer’s protocol, and was then reverse-transcribed into cDNA using oligo (dT) as the primer (Invitrogen). Relative quantitative real-time PCR was performed in a Roche Light Cycler 96 real-time PCR system. The real-time PCR results were analyzed and expressed as relative expression of CT (threshold cycle) valuing the 2−ΔΔCt method. The primers used for PEDV and GAPDH were listed below: PEDV-F: 5′-CGTACAGGTAAGTCAATTAC-3′; PEDV-R: 5′-GATGAAGCATTGACTGAA-3′; GAPDH-F: 5′-ACATCATCCCTGCCTCTACTG-3′; GAPDH-R: 5′-CCTGCTTCACCACCTTCTTG-3′.
Virus stock solutions described above (48 h post infection) were serially diluted before they were inoculated on the confluent Vero cell monolayers grown in the 96-well plates, followed by washing three times with PBS. Eight wells were inoculated with 100 μL at each dilution, and plates were incubated at 37 °C with 5% CO2 for 2 days. The wells with syncytium formation, the specific CPE caused by PEDV, were classified as PEDV-positive. PEDV titration was calculated by TCID50 following the Reed-Muench method.
Pharmacokinetics Study of RDV-N in ICR Mice
Six male ICR mice were randomly divided into two groups. Group 1 was received a single intravenous (IV) administration of 25 mg/kg RDV-N dissolved in 5% DMSO, 5% ethanol, 40% PEG300, and 50% saline (pH 5–6 with 0.1 mol/L HCl), and Group 2 was received a single oral (PO) administration of 50 mg/kg RDV-N dissolved in DMSO/0.5% HPMC (5/95, v/v). The blood sample was collected at 5 min, 15 min, 30 min, 1.0 h, 2.0 h, 4.0 h, 8.0 h, and 24 h post-dosing, respectively, and the separated plasma was analyzed by LC/MS/MS. Mean plasma concentrations of RDV-N were used to calculate the pharmacokinetic parameters by noncompartmental analysis.
Acute Toxicity Study of RDV-N in ICR Mice
Fifteen male ICR mice were randomized into three treatment groups, with five animals per group. The three groups of animals were dosed once with RDV-N at 200, 500, and 1000 mg/kg orally, respectively (formulation: 5% DMSO + 5% Solutol HS15 + 90% saline). After administration, the mice were observed for 7 days (general signs, behavioral observation, body weight, and food consumption).
Metabolism of RDV and GS-441524 in Vero E6 Cells
Vero E6 cells were seeded in a 6-well plate at 3.6 × 105 cells/well. After incubation for 24 h, half of the culture media (89% DMEM + 10% FBS + 1% sodium pyruvate) was removed from each well followed by the addition of 20 µmol/L RDV or RDV-N dissolved in the culture media and DMSO (99/1, v/v). The final concentration of RDV or RDV-N was 10 µmol/L (n = 3). Twenty-four hours later, the cells were harvested and lysed in 100 µL methanol/water (7/3, v/v). The nucleoside triphosphate metabolite was analyzed by LC/MS/MS.
Cytotoxic Activities of RDV, RDV-N, and NHC
The cytotoxic effects of RDV, RDV-N, and NHC towards Vero E6 cell were determined before the antiviral assay. As shown in Fig. 2, both of RDV and RDV-N exhibited low cytotoxicity against Vero cell line with the maximal non-toxic concentrations (MNTC) of 125 µmol/L, and NHC showed a higher cytotoxicity with MNTC of 31.25 µmol/L.
Anti-PEDV Activities of RDV, RDV-N, and NHC
PEDV infection of Vero cells can cause cytopathic effect (CPE). To determine whether the three nucleoside analogs possessed ant-PEDV activities, we investigated their effect on the morphological changes of PEDV-infected Vero E6 cells. As shown in Fig. 3, Vero E6 cells uninfected by PEDV were mainly in polygonal or irregular shape with clear outline (Fig. 3A), and not affected by 0.1% DMSO (Fig. 3B), while PEDV significantly caused cell fusion and the normal morphology of cells could not be observed (Fig. 3C). For the experiment groups, the PEDV-induced CPE was obviously blocked by the treatment with RDV, RDV-N, and NHC at the concentration of 0.5 μmol/L, 0.2 μmol/L, and 1.0 μmol/L, respectively (Fig. 3D–3F, Figures of high concentrations were not shown).
To measure the antiviral activities of the three compounds against PEDV, we used quantitative real-time RT-PCR (qRT-PCR) and TCID50 assay to determine the viral loads and titers in the infected cells, respectively. It was obvious to find that the viral genomic copies, as well as the viral titer, were decreased by all the three compounds in a dose-dependent manner at 48 h post infection (Fig. 4). Among them, RDV-N exhibited the strongest antiviral activity, and the virus replication was completely inhibited at the concentration of 2.0 μmol/L. Further, the EC50 values of them were determined at 72 h post infection using qRT-PCR. RDV-N had an EC50 value of 0.31 μmol/L which was twice active as its phospharamidate prodrug, RDV (EC50 = 0.74 μmol/L), and 3-folds more potent than NHC (EC50 = 1.17 μmol/L), shown in Fig. 5.
Moreover, we used an indirect immuno-fluorescence assay (IFA) to further confirm the anti-PEDV capacity of RDV-N. The viral protein expression level could be regarded as an indicator of viral quantity. From Fig. 6B and 6C, it can be found that the fluorescence intensity was significantly decreased in the presence of 0.2 μmol/L RDV-N, which strongly supported the potent antiviral activity of RDV-N.
Pharmacokinetics, In Vitro Metabolism and Acute Toxicity Studies of RDV-N
The pharmacokinetics of RDV-N was studied in ICR mice. As a nucleoside, RDV-N displayed poor water solubility and low lipophilicity. Predictably, this nucleoside demonstrated a low bioavailability (15.7%) in mice (Table 1). After oral administration, RDV-N rapidly reached the maximal plasma concentration within 1 h, and was eliminated quickly, similar to the data of intravenous administration. As an antiviral nucleoside, the active form of RDV-N was the nucleoside triphosphate (NTP) metabolite that mainly resided in tissues, and could hardly be detected in plasma, so we analyzed the in vitro metabolism of RDV-N and RDV in Vero E6 cells. As shown in Fig. 7, the two compounds were found to be metabolized to the corresponding triphosphate, and RDV-N gave a higher level than RDV (11.1 ± 2.5 vs 5.5 ± 1.8 pmol/million cells), which was consistent with the in vitro antiviral activities. For the acute toxicity study, the result showed that oral administration of RDV-N at the maximal dose of 1000 mg/kg did not cause animal death or marked toxic reactions.
Porcine Coronavirus Phylogenetic Analysis
For RNA viruses, RdRp is the specific target of nucleoside antivirals, and the sequence similarity across different viruses is predictive for the antiviral spectrum of this kind of antivirals. Therefore, we performed an RdRp sequence similarity analysis among the six porcine coronaviruses (PEDV, PDCoV, TGEV, PRCV, PHEV, and SADS). The result indicated that PEDV (two strains: PEDV-CV777 and PEDV-SDSX16) shared a > 70% percent identity with SADS, TGEV, and PRCV, and a 60% percent identity with PHEV, but for porcine deltacoronavirus (PDCoV), the identity was only ~49%, shown in Fig. 8A.
It was reported that a Leu at 483 residue of deltacoronavirus RdRp, may be associated with partial resistance to RDV (Brown et al. 2019). Accordingly, we analyzed the 483 residue of the RdRps of the six porcine coronaviruses. It was found that only PDCoV harbored a Leu at the 483 position, where was a Phe for the other viruses (Fig. 8B). The coronavirus RdRps contain four highly conserved sequence motifs (A–D) that are involved in the catalytic process, and the functions of Motif B (substrate binding) and Motif C (positioning of the template-primer and facilitating the nucleotide incorporation) are well understood (Xu et al. 2003). We mapped the amino acid residues of these functional domains of the six porcine coronaviruses. The result indicated that the functional domain sequences (Motif A–G) of the two PEDV strains were 100% identical, and the viruses, including PRCV, TGEV, and SADS shared a high similarity (> 90%) in Motif B and C with PEDV (Fig. 8C).
As is known, antiviral nucleosides need to be converted to the triphosphate active forms to inhibit viral replication by acting as chain terminators or inducing viral lethal mutagenesis. During this process, the first phosphorylation step is regarded as the rate-limiting step (Jordheim et al. 2013). RDV is a phosphoramidate prodrug which can bypass the first step of phosphorylation. Such nucleoside prodrug form is characterized by many advantages (enhancing antiviral activity, improving pharmacokinetics properties, increasing therapeutic index, etc.) and has been widely applied in the antiviral drug discovery for hepatitis viruses (Mehellou et al. 2018). In our study, RDV exhibited lower anti-PEDV activity compared with its parent nucleoside (RDV-N), which was likely due to the deficiency of relevant esterases required to release the RDV nucleoside monophosphate in Vero E6 cells. In another aspect, it can be also speculated that the first phosphorylation step of RDV-N was not a major constraint to its antiviral effect. NHC, a nucleoside discovered very early has been extensively studied (Yoon et al. 2018). The 5′-isobutyrate ester prodrug of NHC, EIDD-2801 is now being evaluated for treating SARS-CoV-2 infection in Phase II/III clinical trials, and this drug shows favorable safety and pharmacokinetics properties based on the recently reported results of phase I clinical studies (Painter et al. 2020). As a broad-spectrum antiviral nucleoside analog, EIDD-2801 is worthy of further studies in the treatment of other viral diseases.
RDV-N proved to be a very potent inhibitor of feline infectious peritonitis virus (FIPV), and could achieve a 100% cure rate in an experimental FIPV infection of cats by subcutaneous administration at a dose of 5 mg/kg or 2 mg/kg (Murphy et al. 2018). Our pharmacokinetics study in mice indicated that the oral bioavailability of RDV-N was low (15.7%), so this nucleoside is better to be administered by parenteral routes. Since mice have high levels of a serum esterase (carboxylesterase 1c, Ces1c) that is capable of hydrolyzing RDV, the pharmacokinetics study of RDV, as well as the in vivo antiviral assay was suggested to be performed in Ces1c−/− mice, and the relevant data are now available in several documents (Pruijssers et al. 2020; Sheahan et al. 2017, 2020a). Of note, RDV-N showed a good safety profile in cats, as evidenced by our acute toxicity study in mice. In a previous study, the cytotoxicity between RDV and RDV-N has been compared using a panel of human cell lines and primary cells. The result indicated that RDV with CC50 values in a range of 1.7–15.0 µmol/L was much more cytotoxic than RDV-N (CC50 > 100 µmol/L) (Warren et al. 2016). Indeed, the phosphoramidate ProTide approach is a liver-targeting technique because the esterases required to activate this prodrug are abundant in liver (Murakami et al. 2010). The clinical studies of RDV in patients revealed that the most common side effect was increased transaminases (Fan et al. 2020), which may be likely related to the properties of this prodrug. RDV-N was thought to have advantages over RDV for the treatment of COVID-19, and now it is being evaluated at the preclinical stage (Yan and Muller 2020). Accordingly, for PED that is an intestinal infectious disease, RDV-N may deserve further study to evaluate its therapeutic potential against this disease.
Besides PEDV, there are other coronaviruses which also can cause severe disease in the porcine herds (Wang et al. 2019). By analyzing the RdRp sequence similarity of six porcine coronaviruses, we found that PDCoV, an enteropathogenic coronavirus that causes serious vomiting and diarrhea in suckling piglets, exhibits a lower sequence similarity (~ 50%) among them. However, this virus is still susceptible to the antiviral activity (EC50 = 0.02 μmol/L) of RDV as reported in a recent research (Brown et al. 2019). As for the RdRp functional domains, which are responsible for binding with antiviral nucleotide and catalyzing the incorporation process, high sequence similarity was observed among PEDV, PRCV, TGEV, and SADS. Therefore, the three compounds, especially RDV and RDV-N are likely to be active against some of the other porcine coronaviruses.
In summary, we discovered that the broad-spectrum antiviral nucleoside analogs, RDV, RDV-N, and NHC were all potent PEDV replication inhibitors. Among them, RDV exhibited a promising prospect for the treatment of PEDV infection. It is also meaningful to investigate the antiviral potential of RDV-N against other porcine coronaviruses, and make some structural modifications on the scaffold to increase its oral bioavailability.
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:e00221-18
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, Members A-SG (2020) Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383:1813–1826
Brown AJ, Won JJ, Graham RL, Dinnon KH 3rd, Sims AC, Feng JY, Cihlar T, Denison MR, Baric RS, Sheahan TP (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res 169:104541
Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, Feng JY, Ray AS, Kim CU (2012) Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett 22:2705–2707
Cho HM, Ha TK, Dang LH, Pham HT, Tran VO, Huh J, An JP, Oh WK (2019) Prenylated phenolic compounds from the leaves of Sabia limoniacea and their antiviral activities against porcine epidemic diarrhea virus. J Nat Prod 82:702–713
Fan Q, Zhang B, Ma J, Zhang S (2020) Safety profile of the antiviral drug remdesivir: an update. Biomed Pharmacother 130:110532
Fox JJ, Van Praag D, Wempen I, Doerr IL, Cheong L, Knoll JE, Eidinoff ML, Bendich A, Brown GB (1959) Thiation of nucleosides. II. Synthesis of 5-methyl-2′-deoxycytidine and related pyrimidine nucleosides. J Am Chem Soc 81:178–187
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Munoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A (2020) Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 383:1827–1837
Gong L, Lin Y, Qin J, Li Q, Xue C, Cao Y (2018) Neutralizing antibodies against porcine epidemic diarrhea virus block virus attachment and internalization. Viro J 15:133
Huan CC, Wang HX, Sheng XX, Wang R, Wang X, Mao X (2017) Glycyrrhizin inhibits porcine epidemic diarrhea virus infection and attenuates the proinflammatory responses by inhibition of high mobility group box-1 protein. Arch Virol 162:1467–1476
Jordheim LP, Durantel D, Zoulim F, Dumontet C (2013) Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 12:447–464
Lee C (2015) Porcine epidemic diarrhea virus: an emerging and re-emerging epizootic swine virus. Virol J 12:193
Li Y, Wu Q, Jin Y, Yang Q (2019) Antiviral activity of interleukin-11 as a response to porcine epidemic diarrhea virus infection. Vet Res 50:111
Ma Y, Zhang Y, Liang X, Lou F, Oglesbee M, Krakowka S, Li J (2015) Origin, evolution, and virulence of porcine deltacoronaviruses in the United States. mBio 6:e00064
Mehellou Y, Rattan HS, Balzarini J (2018) The ProTide Prodrug Technology: from the concept to the clinic. J Med Chem 61:2211–2226
Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA (2010) Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 285:34337–34347
Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, Liepnieks M, Pedersen NC (2018) The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol 219:226–233
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR (2020) Human safety, tolerability, and pharmacokinetics of a novel broad-spectrum oral antiviral compound, molnupiravir, with activity against SARS-CoV-2. medRxiv:1–32
Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP (2020) Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep 32:107940
Purohit MK, Poduch E, Wei LW, Crandall IE, To T, Kain KC, Pai EF, Kotra LP (2012) Novel cytidine-based orotidine-5′-monophosphate decarboxylase inhibitors with an unusual twist. J Med Chem 55:9988–9997
Seley-Radtke KL, Yates MK (2018) The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold. Antiviral Res 154:66–86
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:eaal3653
Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS (2020a) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS (2020b) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12:eabb5883
Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL (2017) Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 60:1648–1661
Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324:1048–1057
Tong T, Hu H, Zhou J, Deng S, Zhang X, Tang W, Fang L, Xiao S, Liang J (2020) Glycyrrhizic-acid-based carbon dots with high antiviral activity by multisite inhibition mechanisms. Small 16:e1906206
Valencia DN (2020) Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2. Cureus 12:e7386
Wang Q, Vlasova AN, Kenney SP, Saif LJ (2019) Emerging and re-emerging coronaviruses in pigs. Curr Opin Virol 34:39–49
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381–385
Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG, Ding J (2003) Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res 31:7117–7130
Yan VC, Muller FL (2020) Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment. ACS Med Chem Lett 11:1361–1366
Yang JL, Ha TK, Dhodary B, Pyo E, Nguyen NH, Cho H, Kim E, Oh WK (2015) Oleanane triterpenes from the flowers of Camellia japonica inhibit porcine epidemic diarrhea virus (PEDV) replication. J Med Chem 58:1268–1280
Yates MK, Seley-Radtke KL (2019) The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: complex modifications to the nucleoside scaffold. Antiviral Res 162:5–21
Ye G, Wang X, Tong X, Shi Y, Fu ZF, Peng G (2020) Structural basis for inhibiting porcine epidemic diarrhea virus replication with the 3C-like protease inhibitor GC376. Viruses 12:240
Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK (2018) Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother 62:e00766-e818
Zhang F, Chen Y, Ke Y, Zhang L, Zhang B, Yang L, Zhu J (2019) Single Chain Fragment Variable (scFv) antibodies targeting the spike protein of porcine epidemic diarrhea virus provide protection against viral infection in piglets. Viruses 11:58
Zhao P, Wang B, Ji CM, Cong X, Wang M, Huang YW (2018) Identification of a peptide derived from the heptad repeat 2 region of the porcine epidemic diarrhea virus (PEDV) spike glycoprotein that is capable of suppressing PEDV entry and inducing neutralizing antibodies. Antiviral Res 150:1–8
This work was supported by the following funding sources, a grant from the Shanghai Science and Technology Committee in China (Number: 19430750100), the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China (Number: 2018ZX09711002), the Shandong Key Provincial Research and Development Program (2019GNC106044) and the Agricultural Scientific and Technological Innovation Project of Shandong Academy of Agricultural Sciences (CXGC2016B14). We greatly appreciated Dr. Jia Liu and Wenjuan Hu for their help in the metabolism study of RDV and RDV-N.
Conflicts of interest
The authors declare that they have no conflict of interest.
Animal and Human Rights Statement
All animal studies were conducted following protocols approved by the Institutional Animal Care and Usage Committee of Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Rights and permissions
About this article
Cite this article
Xie, Y., Guo, X., Hu, T. et al. Significant Inhibition of Porcine Epidemic Diarrhea Virus In Vitro by Remdesivir, Its Parent Nucleoside and β-d-N4-hydroxycytidine. Virol. Sin. 36, 997–1005 (2021). https://doi.org/10.1007/s12250-021-00362-2
- Porcine epidemic diarrhea virus (PEDV)
- Nucleoside analog
- RNA dependent RNA polymerase (RdRp)
- Antiviral activity